Dr. John Henry Heinzerling II, MD

Dr. Heinzerling practices at Atrium Health Cabarrus in Concord, North Carolina, part of Advocate Health.

Dr. Heinzerling's NPI, 1306045752, was assigned on July 16, 2007. Dr. Heinzerling graduated from UT Southwestern Medical Center in 2007. Dr. Heinzerling holds North Carolina license 2011-01884.

Dr. Heinzerling's primary practice is Atrium Health Cabarrus, at 920 Church St N, Concord, NC 28025 in Cabarrus County. The practice phone is (704) 783-3000.

Dr. Heinzerling's primary practice is Atrium Health Cabarrus in Concord, North Carolina, part of Advocate Health. Dr. Heinzerling is also affiliated with Atrium Health Carolinas Medical Center. The medical group on file is SERO (Southeast Radiation Oncology Group). Dmand AI also links Dr. Heinzerling to 1 more hospital, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heinzerling practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Heinzerling's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Heinzerling is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Heinzerling's licenses on file in 3 states: North Carolina, South Carolina and Virginia.

Dmand AI lists bladder cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Heinzerling treats.

CMS data shows 1,657 Medicare services from Dr. Heinzerling across 16 procedure codes in 2024, for 196 Medicare patients. Medicare paid $127,643 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 196 Medicare patients who saw Dr. Heinzerling in 2024. The largest group is 75 to 84, with 85 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heinzerling's median patient age at 72, with 53% women.

In 2024, Dr. Heinzerling wrote 121 Medicare Part D claims for 65 patients. 83% of them were for generic drugs. CMS names the drug for 59 of them, across 3 drugs with 11 or more claims each, at $591 in total drug cost. In 2022, CMS named 37 claims across 3 drugs.

Dr. Heinzerling accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Heinzerling as offering telehealth.

Dmand AI links 24 papers to Dr. Heinzerling, published from 2011 to 2024. 2017 was the busiest year, with 5. The most frequent topics are Radiosurgery, Lung Neoplasms and Carcinoma, Non-Small-Cell Lung. Dr. Heinzerling has published most often in Int J Radiat Oncol Biol Phys. Dr. Heinzerling's most frequent co-authors are Stuart Heinrich Burri, MD, Roshan Sudhir Prabhu, MD and Robert Dale Timmerman, MD.

Dmand AI links Dr. Heinzerling to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lung Neoplasms and Thoracic Neoplasms.

CMS Open Payments shows 58 general payments to Dr. Heinzerling from 12 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 47% of the total. AstraZeneca Pharmaceuticals LP paid the most, $26,518.

Dr. Heinzerling graduated from UT Southwestern Medical Center in 2007.

Dr. Heinzerling is in network with 18 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.